Dornase Alpha for the Treatment of COVID-19
Keywords
Abstract
Description
Recent studies confirmed the role of immune hyperactivation in the pathogenesis of COVID-19. Immune cells, especially neutrophils, infiltrate pulmonary capillaries that cause acute fibrin deposition and extravasation into the alveolar space. This excessive accumulation of neutrophils constitutes NETs which makes the mucus thick and viscous. The highly viscous mucus lowers the patient's respiratory function and impairs ventilation supporting NETs may play a major role in the disease. As a mechanism, double-stranded DNA constitutes the backbone of NETs and Dornase alfa promotes the clearance of NETs from plasma neutralization. Endogenous Deoxyribonucleases (DNases), which physiologically break up this extracellular DNA, may become overwhelmed by a massive influx of NETs. Clinically, recombinant human DNase I (rhDNase, Dornase Alfa) has the identical primary amino acid sequence with the native human enzyme and has been approved for the management of cystic fibrosis. Daily administration of dornase alfa is effective in the treatment of cystic fibrosis patients improving pulmonary functions. The similarity of mucus secretions in COVID-19 and cystic fibrosis patients by the means of NETs makes Dornase alfa as a therapeutic option in COVID-19.
Progressive COVID-19 pneumonia may be mortal if it is not treated early, causing respiratory failure. The most important factor leading to respiratory failure is hyaline membrane formed by a neutrophil trap that develops in the cavities of the alveoli. Dornase Alpha is thought to have an important contribution by the lysis of this hyalen membrane. In this study, it is aimed to evaluate the effectiveness of Dornase Alpha treatment in case of early and late use in COVID-19 disease.
Patients diagnosed with COVID-19 PCR and / or radiological-clinical findings is included in the study, and this treatment is carried out in 2 patient groups in comparison with the control groups. The groups are:
1. Newly Diagnosed Patient Group I. Dornase Alpha treated group ii. Control group
2. Patient Group Monitored by Mechanical Ventilation I. Dornase Alpha treated group ii. Control group
Dates
| Last Verified: | 04/30/2020 |
| First Submitted: | 06/14/2020 |
| Estimated Enrollment Submitted: | 06/14/2020 |
| First Posted: | 06/15/2020 |
| Last Update Submitted: | 06/14/2020 |
| Last Update Posted: | 06/15/2020 |
| Actual Study Start Date: | 05/24/2020 |
| Estimated Primary Completion Date: | 08/24/2020 |
| Estimated Study Completion Date: | 09/24/2020 |
Condition or disease
Intervention/treatment
Drug: Pulmozyme
Phase
Arm Groups
| Arm | Intervention/treatment |
|---|---|
| Experimental: Newly Diagnosed Patient Group (n=30) I. Dornase Alpha treated group (n=15)
ii. Control group (n=15) | |
| Experimental: Patient Group Monitored by Mechanical Ventilation (n=30) I. Dornase Alpha treated group (n=15)
ii. Control group (n=15) |
Eligibility Criteria
| Ages Eligible for Study | 18 Years To 18 Years |
| Sexes Eligible for Study | All |
| Accepts Healthy Volunteers | Yes |
| Criteria | Inclusion Criteria: - Being 18 or older - Approving the Informed Consent Form - Being diagnosed with COVID-19 with PCR and / or radiological clinical findings - Hospitalization indication according to Ministry of Health criteria Exclusion Criteria: - Pregnant and / or breastfeeding women. - Any known allergy to Dornase Alpha - Being involved in another drug study - Previously diagnosed with chronic lung disease |
Outcome
Primary Outcome Measures
1. Response [3 months]
Secondary Outcome Measures
1. Survival [3 months]
